Nanhua Biology (000504.SZ): Cell therapy-related technologies and products are still in the development stage

Zhitongcaijing · 1d ago

Zhitong Finance App News, Nanhua Biotech (000504.SZ) issued a stock trading risk warning notice stating that currently the company's main business is biomedicine, energy saving and environmental protection. Among them, the biomedical sector mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells, and also cooperates with many clinical research institutions to provide them with cell preparation, testing and other services that meet clinical research requirements. The company's cell therapy-related technology and products are still in the R&D stage, and no innovative drugs have been marketed or entered into clinical trials; the energy saving and environmental protection sector is mainly engaged in lithium carbonate business, waste steel recycling resources, and supporting processing and sales.

The major asset restructuring of the company's original plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. was terminated on January 22, 2026, and the company currently has no CRO business.